Secretariat Lead of the G20’s Global AMR R&D Hub: Could this be you?

Dear All:

As you may know, the G20 are establishing an AMR R&D Hub that will encourage and promote coordinated global action on AMR. The hub will be based in the Berlin office of the German Center for Infection Research (DZIF) and Germany will finance it for the first three years. There is now a public call to recruit the leader of this hub. Here is the key text from the the online job description (emphasis is mine):

In their Declaration from July 7 and 8, 2017 the G20 Leaders “call for a new international R&D Collaboration Hub to maximize the impact of existing and new antimicrobial basic and clinical research initiatives as well as product development”. This Global AMR R&D Hub shall promote high-level coordination and alignment of the existing public and private funding and leverage further investments for AMR R&D initiatives on a national and/or international level. The Global AMR R&D Hub shall become a central platform to provide guidance for governments and non-governmental funders on R&D funding priorities in the field. The scope of the Global AMR R&D Hub is embedded in a comprehensive One Health Approach, comprising human and animal health as well as environmental aspects. Initially, the activities of the Global AMR R&D Hub shall focus on enabling the development of urgently needed products for the prevention, treatment and diagnosis of bacterial infections in humans.

For the implementation of the Global AMR R&D Hub a secretariat with up to five employees (including the position announced below) will be established within the German Center for Infection Research (DZIF) in Berlin, Germany. We are currently searching for one Secretariat Lead (Senior Level).

Could this be you or somebody you know? Please be sure to share this interesting and important job opportunity! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Developing antibiotics for children: There are no easy answers

Aside: If you’ve enjoyed the prior discussions of movies to inspire antibiotic R&D and very apropos given the theme of today’s newsletter, please check out the newly released 4-minute YouTube discussion of a scene from Master and Commander in which antibiotics could have saved a young man’s arm! Dear All (Wonkish alert! There’s a lot of

Vaccines to turn back the tide of antimicrobial resistance

Dear All, As part of their Immunization Agenda 2030: A Global Strategy to Leave No One Behind, WHO have now published an AMR-focused action framework that summarizes ways we should seek to use vaccines both to reduce antibiotic use and to prevent the further emergence of antimicrobial resistance. Here are the links you need —

Stewardship & Access Guide from CARB-X, Wellcome, and partners: Analysis, video chat

Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The State of the World’s Antibiotics in 2021” makes this very clear: “… more people in LMICs (low-middle-income countries) die from lack of access to antimicrobials than from resistant infection.” Hence, CARB-X has

Amended Indian PPL slide / SUPERBUGS Act / Novo REPAIR Global Call

Dear All, Three bits of news you can use… First, when I wrote yesterday about the new Indian Priority Pathogen List (PPL), I said that it was similar to the WHO PPL list except for the addition of Staphylococcus epidermidis (and speculated that this relates to the role of S. epidermidis in neonatal sepsis). Well, it

Scroll to Top